Cerebrospinal beta-amyloid ((1-42)) in early Alzheimer's disease: Association with apolipoprotein E genotype and cognitive decline

Neuroscience Letters

Volumn 284, Issue 1-2, 2000, Pages 85-88

  Riemenschneider, M ^a   Schmolke, M ^b   Lautenschlager, N ^a   Guder, W G ^b   Vanderstichele, H ^c   Vanmechelen, E ^c   Kurz, A ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Klin Chem Inst   (Germany)

^c INNOGENETICS   (Belgium)

Author keywords

Alzheimer's disease; ApoE genotype; Beta amyloid; Biomarker; Cerebrospinal fluid

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; TAU PROTEIN;

ADULT; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROFIBRILLARY TANGLE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL;

AGE FACTORS; AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; APOLIPOPROTEINS E; FEMALE; GENOTYPE; HUMANS; MALE; PEPTIDE FRAGMENTS;

EID: 0034697051     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(00)00976-9     Document Type: Article

References (14)

1. Andreasen N., Hesse C., Davidsson P., Minthon L., Wallin A., Winblad B., Vanderstichele H., Vanmechelen E., Blennow K. Cerebrospinal fluid beta-Amyloid (1-42) in Alzheimer's disease. Arch. Neurol. 56:1999;673-680.
2. Andreasen N., Minthon L., Vanmechelen E., Vanderstichele H., Davidsson P., Winblad B., Blennow K. Cerebrospinal fluid tau and Aβ42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci. Lett. 273:1999;5-8.
3. Galasko D., Chang L., Motter R., Clark C.M., Kaye J., Knopman D., Thomas R., Kholodenko D., Schenk D., Lieberburg I., Miller B., Green R., Basherad R., Kertiles L., Boss M.A., Seubert P. High cerebrospinal fluid tau and low amyloid beta 42 levels in the clinical diagnosis of Alzheimer's disease and relation to apolipoprotein E genotype. Arch. Neurol. 55:1998;937-945.
4. (1-42) and tau levels in CSF. Neurology. 52:1999;1555-1562.
5. Jensen M., Schröder J., Blomberg M., Engvall B., Pantel J., Ida N., Basun H., Wahlund L-O., Werle E., Jauss M., Beyreuther K., Lannfeldt L., Hartmann T. Cerebrospinal fluid Aβ42 is increased early in sporadic Alzheimer's disease and declines with disease progression. Ann. Neurol. 45:1999;504-511.
6. McKhann G., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 34:1984;939-944.
7. Motter R., Vigo-Perlfrey C., Khologdenko D., Barbour R., Johnson-Wood K., Galasko D., Chang L., Miller B., Clark C., Green R., Olson D., Soutwick P., Wolfert R., Munroe B., Lieberburg I., Seubert P., Schenk D. Reduction of β-Amyloid peptide 42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann. Neurol. 38:1995;643-648.
8. Neary D., Snowden J.S., Gustafson L., Passant U., Stuss D., Black S., Freedman M., Kertesz A., Robert P.H., Albert M., Boone K., Miller B.L., Cummings J., Benson D.F. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 51:1998;1546-1554.
9. Pirttila T., Koivisto K., Mehta P.D., Reinikainen K., Kim K.S., Kilkku O., Heinonen E., Soininen H., Riekkinen P. Sr., Wisniewski H.M. Longitudinal study of cerebrospinal fluid amyloid proteins and apolipoprotein E in patients with probable Alzheimer's disease. Neurosci. Lett. 249:1998;21-24.
10. Rebeck G.W., Reiter J.S., Strickland D.K., Hyman B.T. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron. 11:1993;575-580.
11. Román G.C., Tatemichi T.K., Erkinjuntti T., Cummings J.L., Maseu J.C., Garcia J.H., Amaducci L., Orgogozo J.M., Brun A., Hofman A., Moody D.M., O'Brien M.D., Yamaguchi T., Grafman J., Drayer B.P., Bennet D.A., Fisher M., Ogata J., Kokmen E., Bermejo F., Wolf P.A., Gorelick P.B., Bick K.L., Pajeau A.K., Bell M.A., DeCarli C., Culebras A., Korczyn A.D., Bogousslavsky J., Hartmann A., Scheinberg P. Vascular dementia: diagnostic criteria for research studies: report of the NINDS-AIREN International Workshop. Neurology. 43:1993;250-260.
12. Samuels S.C., Silverman J.M., Marin D.B., Peskind E.R., Younkin S.G., Greenberg D.A., Schnur E., Santoro J., Davis K.L. CSF beta-amyloid, cognition, and apoE genotype in Alzheimer's disease. Neurology. 52:1999;547-551.
13. Schmechel D.E.A., Saunders A.M., Strittmatter W.J., Cram B.J., Hulette C.M., Joo S.H., Pericak-Vance M.A., Goldgaber D., Roses A.D. Increased amyloid b-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 90:1993;9649-9653.
14. (1-42) in CSF. Fisher A., Hanin I., Yoshida M. Alzheimer's and Parkinson's diseases. 1998;773-778 Plenum Press, New York.